-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
【Weekly Medical Questions】is a new online column of "NEJM Frontiers of Medicine"
.
This column is based on NEJM Knowledge+, a sister product of the New England Journal of Medicine.
It pushes a question every Wednesday, and announces the answers and detailed explanations on the next day
.
The questions and content seem simple, but they are the core knowledge points and error-prone points of clinical practice; correct answers are not the goal, mastering the main points is the kingly way
.
Ask the doctor every week to help you draw up key points and save you time! Everyone is welcome to leave a message in the comments section
.
Your valuable comments and suggestions will be our best help! A 60-year-old man with a history of type 2 diabetes and chronic obstructive pulmonary disease (COPD) was admitted to the hospital with COPD worsening
.
The patient's medications included insulin glargine (40 U per day), metformin (two times per day, 1000 mg), as well as fluticasone and salmeterol inhalers
.
The patient reported a recent glycosylated hemoglobin level of 7.
0% (reference range is 3.
8~5.
6)
.
Physical examination: The patient has mild breathing difficulties, body temperature is 37.
9°C, blood pressure is 146/90 mmHg, heart rate is 102 beats/min, respiratory rate is 22 beats/min, and oxygen saturation is 90% under the condition of nasal cannula oxygen inhalation of 4L/min
.
The patient is 165.
1 cm tall, weighs 79 kg, and has a BMI of 29
.
Wheezing can be heard in both lungs, but no signs of lung consolidation
.
The patient started taking levofloxacin, prednisone (60 mg daily), and nebulized salbutamol and ipratropium bromide
.
Daily use of insulin continued, and metformin was discontinued
.
On the second day of admission, the blood glucose level at random was between 200 and 300 mg/dL (reference range, <140)
.
Which of the following is the best treatment strategy for this patient’s hyperglycemia? A.
Divide the dose of insulin glargine into two halves and administer it twice a day.
B.
Increase mealtime insulin.
C.
Replace prednisone with an equivalent dose of dexamethasone.
D.
Start a single long-acting sulfonylurea drug.
Treatment E.
The answer to the question of increasing the dose of insulin glargine is actually hidden in the stem and abstract
.
Do you have the answer? If you are not sure, you can share the content with your friends, and the discussion can make people think more clearly
.
While answering the questions, please leave a message with your answers and diagnosis and treatment ideas to us
.
The answer will be announced tomorrow, and we will see you or leave! Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.
.
This column is based on NEJM Knowledge+, a sister product of the New England Journal of Medicine.
It pushes a question every Wednesday, and announces the answers and detailed explanations on the next day
.
The questions and content seem simple, but they are the core knowledge points and error-prone points of clinical practice; correct answers are not the goal, mastering the main points is the kingly way
.
Ask the doctor every week to help you draw up key points and save you time! Everyone is welcome to leave a message in the comments section
.
Your valuable comments and suggestions will be our best help! A 60-year-old man with a history of type 2 diabetes and chronic obstructive pulmonary disease (COPD) was admitted to the hospital with COPD worsening
.
The patient's medications included insulin glargine (40 U per day), metformin (two times per day, 1000 mg), as well as fluticasone and salmeterol inhalers
.
The patient reported a recent glycosylated hemoglobin level of 7.
0% (reference range is 3.
8~5.
6)
.
Physical examination: The patient has mild breathing difficulties, body temperature is 37.
9°C, blood pressure is 146/90 mmHg, heart rate is 102 beats/min, respiratory rate is 22 beats/min, and oxygen saturation is 90% under the condition of nasal cannula oxygen inhalation of 4L/min
.
The patient is 165.
1 cm tall, weighs 79 kg, and has a BMI of 29
.
Wheezing can be heard in both lungs, but no signs of lung consolidation
.
The patient started taking levofloxacin, prednisone (60 mg daily), and nebulized salbutamol and ipratropium bromide
.
Daily use of insulin continued, and metformin was discontinued
.
On the second day of admission, the blood glucose level at random was between 200 and 300 mg/dL (reference range, <140)
.
Which of the following is the best treatment strategy for this patient’s hyperglycemia? A.
Divide the dose of insulin glargine into two halves and administer it twice a day.
B.
Increase mealtime insulin.
C.
Replace prednisone with an equivalent dose of dexamethasone.
D.
Start a single long-acting sulfonylurea drug.
Treatment E.
The answer to the question of increasing the dose of insulin glargine is actually hidden in the stem and abstract
.
Do you have the answer? If you are not sure, you can share the content with your friends, and the discussion can make people think more clearly
.
While answering the questions, please leave a message with your answers and diagnosis and treatment ideas to us
.
The answer will be announced tomorrow, and we will see you or leave! Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.